title: Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
abstract: Chronic hepatitis B (CHB) is a dynamic disease that is influenced by host and virological factors. The management of CHB has become more complex with the increasing use of long-term oral nucleos⁄tide analogue antiviral therapies and the availability of novel diagnostic assays. Furthermore, there is often a lack of robust data to guide optimal management such as the selection of therapy, duration of treatment, potential antiviral side effects and the treatment of special populations. In November 2011, the Canadian Liver Foundation and the Canadian Association for the Study of the Liver convened a consensus conference to review the literature and analyze published data, including other international expert guidelines on CHB management. The proceedings of the consensus conference are summarized and provide updated clinical practice guidelines to assist Canadian health care providers in the prevention, diagnosis, assessment and treatment of CHB.
authors.affiliation: Department of Medicine, University of Calgary, Alberta.
authors.forename: Carla S
authors.initials: CS
authors.lastname: Coffin
authors.forename: Scott K
authors.initials: SK
authors.lastname: Fung
authors.forename: Mang M
authors.initials: MM
authors.lastname: Ma
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000488:Allied Health Personnel; D000914:Antibodies, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use; D002170:Canada / Q000453:epidemiology; D060085:Coinfection; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D006147:Guanine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006514:Hepatitis B Surface Antigens / Q000097:blood; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D006515:Hepatitis B virus / Q000378:metabolism; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D006526:Hepatitis C / Q000453:epidemiology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007674:Kidney Diseases / Q000628:therapy / Q000821:virology; D008099:Liver / Q000473:pathology; D063065:Organophosphonates / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy; D000068698:Tenofovir
chemical_list: D000914:Antibodies, Viral; D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D063065:Organophosphonates; C413685:entecavir; D006147:Guanine; D007372:Interferons; D000068698:Tenofovir; D000225:Adenine